Vumerity
diroximel fumarate · Biogen Netherlands B.V.
AUTHORISED IN THE EUWhat Vumerity is used for
Vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see Section 5.1 for important information on the populations for which efficacy has been established).
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Vumerity
- Active substance
- diroximel fumarate
- Disease area
- Multiple Sclerosis, Relapsing-Remitting
- Medicine group
- Immunosuppressants
- ATC code
- L04AX07
- Marketing authorisation holder
- Biogen Netherlands B.V.
- Authorised in the EU since
- 2021
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Vumerity used for?
Vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see Section 5.1 for important information on the populations for which efficacy has been established).
What is the active substance in Vumerity?
Vumerity contains diroximel fumarate.
Who makes Vumerity?
The EU marketing authorisation holder is Biogen Netherlands B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU